⌘K
t
On March 19, 2024, ImmuPharma PLC announced the grant of unapproved share options, with the transactions dated March 18, 2024. Executive Directors Tim McCarthy, Tim Franklin, and Sebastien Goudreau received 8,000,000, 6,500,000, and 5,000,000 share options respectively, and an additional 5,500,000 options were awarded to other employees/contractors. All options have an exercise price of £0.02, are valid for 10 years, and will vest at the later of a new commercial deal of significant value or three years from issue.
| Date | 19 Mar 2024 |
| Time | 07:00:11 |
| Category | Director/PDMR dealings |
| ID | 3189H |
19 March 2024
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Share Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.
The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting conditions which reflect the corporate objective of restoring and enhancing shareholder value as follows:
Tim McCarthy 8,000,000 share options (exercise price £0.02)
Tim Franklin 6,500,000 share options (exercise price £0.02)
Sebastien Goudreau 5,000,000 share options (exercise price £0.02)
In addition, 5,500,000 unapproved Share Options have been awarded to other employees/contractors with the same performance conditions.
Share Option Period: All Share Options are valid for 10 years from the date of issue.
Time and Performance Conditions:
All Share Options will vest at the latter of:
· When the Company has completed a new commercial deal of significant value; and
· 3 years from the date of issue
The Remuneration Committee will determine when these conditions have been met.
ENDS
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
|
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Tim McCarthy |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chairman and Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ImmuPharma PLC |
|
|
b) |
LEI |
213800VZKGHXC7VUS895 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010 |
|
|
b) |
Nature of the transaction |
Grant of share options over new Ordinary Shares |
|
|
c)
|
Price(s) and volume(s)
|
Exercise Price |
Volume |
|
2 pence |
8,000,000 |
||
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|
|
e) |
Date of the transaction |
18 March 2024 |
|
|
f) |
Place of the transaction |
n/a |
|
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Tim Franklin |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Operating Officer |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ImmuPharma PLC |
|
|
b) |
LEI |
213800VZKGHXC7VUS895 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010 |
|
|
b) |
Nature of the transaction |
Grant of share options over new Ordinary Shares |
|
|
c)
|
Price(s) and volume(s)
|
Exercise Price |
Volume |
|
2 pence |
6,500,000 |
||
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|
|
e) |
Date of the transaction |
18 March 2024 |
|
|
f) |
Place of the transaction |
n/a |
|
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Sebastien Goudreau |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Director |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ImmuPharma PLC |
|
|
b) |
LEI |
213800VZKGHXC7VUS895 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010 |
|
|
b) |
Nature of the transaction |
Grant of share options over new Ordinary Shares |
|
|
c)
|
Price(s) and volume(s)
|
Exercise Price |
Volume |
|
2 pence |
5,000,000 |
||
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|
|
e) |
Date of the transaction |
18 March 2024 |
|
|
f) |
Place of the transaction |
n/a |
|